In the first graph, the date should read: Thursday, November 15 (sted Wednesday, November 14).
The corrected release reads:
SUCAMPO PHARMACEUTICALS ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 2012 CREDIT SUISSE HEALTHCARE CONFERENCE
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that it will webcast its corporate presentation at the 2012 Credit Suisse Healthcare Conference on Thursday, November 15, 2012, at 11:30 am Mountain, or 1:30 pm Eastern.
The presentation will be webcast live and may be accessed from the Event Calendar page of Sucampo’s website at
. A replay of the webcast will also be available on the Company’s website for several days after the live event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., a global pharmaceutical company, is focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer. For more information, please visit
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo’s ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo’s patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.